– USA, GA – Accuitis, Inc. today announced the closing of a $1 million Preferred financing round. The financing was a private placement with a significant investment from the recently formed Atlanta based, Bio/Med Investor Network. The Georgia Research Alliance, through its GRA Ventures program, has also granted a Phase IIIA loan. Accuitis expects to use proceeds from this financing to fund continued development of Accuitis’s first in class topical proteasome inhibitor (ACU-D1) for the treatment of Rosacea into Phase 1-2 clinical trials in 2016.
Accuitis has also elected Geoff Meacham, PhD to the Board of Directors. Dr. Meacham is managing director and senior research analyst covering the biopharmaceutical industry at Barclays. Previously, Meacham was with J.P.Morgan as a senior biotechnology analyst, and was an equity analyst at UBS, following early-stage biotech and life science companies. He has also worked in the pharmaceutical industry in a research-and-development capacity, Meacham holds a PhD in molecular cell biology from UAB and a bachelor’s degree in biology/microbiology from the University of Georgia.
About Accuitis, Inc.
Accuitis, Inc., headquartered in Cumming, GA, is a pre-clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic diseases of the skin and eye. Accuitis lead product is a topical proteasome inhibitor discovered at Emory University and is focused on treating Rosacea a dermato-ophthalmic condition which effects over 43 million people in the US & Western Europe, and other inflammatory skin diseases. A start-up out of the Emory Univerity tech transfer office, Accuitis is a GRA Ventures portfolio company and has received significant support from the Georgia Research Alliance.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.